Bispecific antibodies are engineered proteins that bind two different targets at once, and as of late 2023 the U.S. Food and Drug Administration had approved 11 of them, with the majority designed to fight cancer by redirecting a patient’s own immune cells toward tumor cells. The concept sounds almost deceptively simple: take an antibody, give it two different binding arms instead of the usual matched pair, and let it physically connect things that would not ordinarily meet. In practice, getting that idea from a laboratory curiosity to a clinical product took decades of structural engineering, manufacturing breakthroughs, and creative solutions to serious side effects. The result is a class of therapies that is reshaping treatment for blood cancers, hemophilia, and retinal disease, with solid tumors as the next frontier.
How Bispecific Antibodies Actually Work
A conventional antibody has two identical arms, both recognizing the same molecular target. A bispecific antibody swaps one arm for something different, so the molecule can grab two distinct targets simultaneously. The most common use of this dual grip in cancer therapy is T-cell engagement: one arm latches onto a marker on the surface of a tumor cell, while the other arm grabs CD3, a protein found on T cells. By physically bridging the two cells, the antibody forces them into close proximity, triggering the T cell to attack. This artificial connection mimics the natural “immunological synapse” that forms when a T cell recognizes a threat, but it bypasses the usual recognition step entirely. The T cell does not need to independently identify the cancer cell; it is essentially handed the target.
Research into how these synapses form has revealed that the distance between the two cell membranes matters a great deal. Studies using engineered T-cell engagers of varying sizes found that designs producing close membrane-to-membrane contact performed better at triggering T-cell killing, cytokine release, and the activation of downstream signaling molecules. Flexibility of the antibody construct also played a role: a stiffer design with a longer reach could sometimes match the potency of a more compact but floppy one, because rigidity compensated for the extra distance. The interplay between contact distance and flexibility determines much of a bispecific antibody’s potency in practice.
Beyond simply connecting cells, T-cell-engaging bispecific antibodies can produce a “bystander effect.” When the immunological synapse forms and T cells activate, the resulting burst of cytokines and chemokines does not just damage the targeted cancer cell. Nearby tumor cells that lack the target antigen can also sustain damage, with the extent depending on the proportion of target-positive cells in the area and how long the interaction lasts. This bystander killing is a double-edged feature: it can help clear tumors that have mixed populations of target-positive and target-negative cells, but it also raises concerns about collateral damage to healthy tissue.
The Structural Formats Behind Approved Products
Not all bispecific antibodies look alike under a microscope. Two broad design families dominate the approved products. One is based on small single-chain variable fragments that lack the tail region (called the Fc) of a natural antibody. The other retains the full antibody shape, producing a larger, IgG-like molecule with an asymmetric structure where the two arms differ. Each format brings trade-offs in how long the drug lasts in the body, how it interacts with the immune system, and how easy it is to manufacture.
The Fc region, when present, is not just structural scaffolding. Modifications to this tail can extend the antibody’s half-life in the bloodstream, tune how strongly it activates immune effector cells, and improve overall stability. Fc engineering strategies also make it possible to force the two different heavy chains of a bispecific antibody to pair correctly during manufacturing, which is one of the biggest technical headaches in the field. Without such engineering, mixing two different antibody halves in a single production cell yields a messy soup of mispaired molecules, with the desired bispecific product as only one fraction of the output.
What the FDA Has Approved and Where These Drugs Are Used
By December 2023, 11 bispecific antibody products had received FDA approval. Nine of those were for cancer, and eight of the nine cancer-focused products were CD3 T-cell engagers, meaning they work by redirecting T cells to kill tumor cells. The remaining approvals cover non-cancer conditions, demonstrating the flexibility of the bispecific concept beyond oncology.
Blood Cancers
The strongest track record for bispecific antibodies is in hematologic malignancies, particularly B-cell lymphomas and multiple myeloma. In lymphoma, products targeting CD20 on tumor cells while engaging T cells via CD3 have shown striking activity. Early clinical data for one such antibody in patients with relapsed or refractory follicular lymphoma showed an overall response rate above 90% and a complete response rate above 70% at effective doses. In diffuse large B-cell lymphoma, a harder-to-treat disease, complete responses were observed in a majority of patients at higher doses, including some who had already failed CAR-T cell therapy.
Multiple myeloma has become another major proving ground. Bispecific antibodies targeting BCMA or GPRC5D on myeloma cells have both reached the market. A meta-analysis pooling data from 30 studies and over 3,200 patients found that BCMA-targeted and GPRC5D-targeted bispecific antibodies had comparable overall response rates of roughly 65% and 70%, respectively. Both classes are now considered frontline options for patients whose disease has relapsed after multiple prior treatments.
Perhaps most compelling is the emerging evidence that bispecific antibodies can rescue patients whose disease progresses even after CAR-T cell therapy, which was previously seen as the last high-potency option. In an international study of 139 myeloma patients who relapsed after CAR-T, those treated with bispecific antibodies (talquetamab or teclistamab) had substantially higher response rates and longer survival than those given conventional drug combinations. The bispecific antibody group achieved overall response rates of 64% to 79%, compared to 26% to 30% for patients on standard drug regimens. Bispecific antibodies appeared to overcome the poor prognosis associated with early relapse and extramedullary disease, leading the study authors to suggest them as the standard of care after CAR-T failure.
Beyond Cancer
Two approved bispecific antibodies have nothing to do with oncology, and they illustrate how versatile the platform can be. Emicizumab, approved for hemophilia A, does not engage T cells at all. Instead, it mimics the function of a missing clotting factor by bridging two proteins in the coagulation cascade, activated factor IX and factor X, restoring the clotting reaction that is deficient in hemophilia A patients. Unlike the clotting factor it replaces, emicizumab does not require activation to function, which gives it fundamentally different behavior in lab tests and in the body.
Faricimab takes the bispecific concept into ophthalmology. Injected directly into the eye, it simultaneously blocks two pathways that drive abnormal blood vessel growth and leakage: VEGF-A and angiopoietin-2. By hitting both targets at once, faricimab achieves visual and anatomical results comparable to existing anti-VEGF treatments but with fewer injections needed over time, reducing the burden on patients who otherwise face monthly or bimonthly eye injections for conditions like wet age-related macular degeneration and diabetic macular edema.
Why Solid Tumors Remain a Harder Problem
If bispecific antibodies are so effective in blood cancers, the obvious question is why they have not transformed solid tumor treatment at the same pace. The answer involves several compounding obstacles. Solid tumors sit behind physical barriers that circulating antibodies struggle to penetrate. The tumor microenvironment is often immunosuppressive, actively shutting down T cells that do manage to infiltrate. And the targets available on solid tumor surfaces tend to also appear on some healthy tissues, creating “on-target, off-tumor” toxicity where the drug damages normal cells expressing the same marker.
Researchers have identified promising targets in specific solid cancers, including PSMA in prostate cancer, DLL3 in certain lung cancers, and EGFRvIII in glioblastoma. But clinical progress has been slowed by toxicity issues, short drug half-lives in the harsh tumor microenvironment, and the difficulty of getting enough drug into a dense, poorly vascularized tumor mass. Early-generation bispecific T-cell engagers designed for solid tumors ran into problems with their Fc regions triggering unwanted immune reactions, prompting the development of Fc-silenced, half-life-extended versions. The field is active and optimistic, but the honest assessment is that solid tumor bispecific antibodies remain largely in clinical trials rather than in routine clinical use.
Managing the Side Effects
The potency that makes bispecific T-cell engagers effective against cancer also produces their most serious side effect: cytokine release syndrome, or CRS. When the drug forces T cells to activate en masse, those T cells release a flood of inflammatory signaling molecules. Mild CRS feels like a bad flu, with fever, chills, and body aches. Severe CRS can cause dangerously low blood pressure, organ damage, and in rare cases can be life-threatening. A related but distinct toxicity, immune effector cell-associated neurotoxicity syndrome (ICANS), involves neurological symptoms ranging from confusion and difficulty speaking to seizures, driven by inflammation that disrupts the blood-brain barrier.
Clinicians have developed practical strategies to manage both. The most important is step-up dosing: starting with small “priming” doses well below the therapeutic level, then gradually ramping up to the full dose over the first week or two of treatment. This approach works because repeated low-level T-cell activation depletes the initial cytokine surge, so by the time the patient reaches the full dose, the immune system’s inflammatory response has been dampened. For elranatamab, a bispecific antibody used in myeloma, researchers found that peak drug concentration in the blood on the first day of treatment directly correlated with CRS risk. Giving the drug subcutaneously rather than intravenously produced a slower, lower peak concentration, further reducing CRS incidence. The optimized regimen uses two small priming doses before the first full-strength dose on day eight.
When CRS does occur despite precautions, the standard rescue medications are tocilizumab (which blocks the inflammatory cytokine IL-6) and corticosteroids. These are the same drugs used to manage CRS from CAR-T cell therapy, and most oncology centers are now experienced with their use. The practical upshot is that CRS, while still a real concern, is increasingly predictable and manageable, which has opened the door to outpatient administration for some bispecific antibodies. Moving treatment out of the hospital and into clinic settings reduces costs and improves patient access, a shift that several institutions are actively pursuing.
Bispecific Antibodies Versus CAR-T Cell Therapy
Both bispecific antibodies and CAR-T cell therapy redirect T cells against cancer, but the practical differences between them are substantial. CAR-T therapy involves removing a patient’s T cells, genetically engineering them in a laboratory to recognize a specific tumor target, expanding them, and infusing them back. The process takes weeks, costs upward of several hundred thousand dollars, and requires specialized manufacturing facilities. The payoff is impressive: durable complete response rates in the range of 40% to 60% in relapsed large B-cell lymphoma, with some patients remaining in remission years later.
Bispecific antibodies skip all of that complexity. They are manufactured drugs, available off the shelf, and can be administered the same day they are prescribed. There is no individualized cell manufacturing, no weeks of waiting while the patient’s disease may progress. The safety profile generally favors bispecific antibodies as well, with lower rates of severe CRS and neurotoxicity compared to CAR-T, which is why outpatient dosing is feasible. The trade-off is in durability: while response rates to bispecific antibodies are promising, long-term follow-up data are still maturing, and it remains unclear whether these drugs produce the same lasting remissions seen with the best CAR-T outcomes. For now, the two approaches are increasingly viewed as complementary rather than competing, with bispecific antibodies offering an accessible option for patients who cannot wait for or tolerate CAR-T manufacturing, and potentially serving as a rescue therapy when CAR-T fails.
How Tumors Develop Resistance
As with nearly every cancer therapy, some tumors eventually find a way to escape bispecific antibodies. The most straightforward resistance mechanism is antigen loss: the tumor stops expressing the surface molecule that the antibody’s cancer-targeting arm binds to. This can happen through deletions in the chromosome carrying the target gene, point mutations that alter the protein’s shape enough that the antibody no longer recognizes it, or epigenetic silencing where the gene is effectively switched off without being physically damaged. Once the target disappears, the bispecific antibody has nothing to grab onto and becomes ineffective.
This is one reason researchers are excited about having multiple target options in a single disease. In myeloma, for instance, if a patient’s tumor loses BCMA expression after treatment with a BCMA-targeted bispecific, switching to a GPRC5D-targeted product offers a second chance because the two targets are biologically independent. Antigen loss at one does not predict loss at the other. The availability of bispecific antibodies against different targets within the same cancer type is itself a form of therapeutic resilience that did not exist a few years ago.
The Manufacturing Puzzle
Making a bispecific antibody is harder than making a conventional one, and that difficulty has historically been one of the biggest bottlenecks in the field. A standard antibody has two identical heavy chains and two identical light chains, which naturally pair correctly. A bispecific antibody has two different heavy chains and potentially two different light chains, creating a combinatorial pairing problem. If you express all four chains in the same cell, you get the desired bispecific product plus several mispaired byproducts that must be separated out.
The most established solution is the “knobs-into-holes” approach, where one heavy chain is engineered with a bulky amino acid (“knob”) and the other with a corresponding cavity (“hole”), so the two different heavy chains preferentially pair with each other rather than with themselves. This solves the heavy-chain pairing problem but still leaves the light-chain problem: each light chain could pair with either heavy chain. Researchers have attacked this with charge-based engineering at the interface where heavy and light chains meet, introducing complementary charges so each light chain is electrostatically guided to its correct partner. In one study, this strategy pushed the yield of correctly assembled bispecific antibody above 90% for the majority of antibody pairs tested. Newer computational design methods using tools like Rosetta to model hydrogen-bond networks at chain interfaces have achieved near-complete elimination of light-chain mispairs.
An alternative approach bypasses the in-cell pairing problem entirely by producing each antibody half separately and then combining them in a controlled reaction outside the cell. One recent method fuses temporary molecular “tags” to each chain that force correct pairing, then cleaves those tags off with an enzyme, leaving a clean bispecific antibody behind. These manufacturing innovations matter because they directly affect cost, purity, and ultimately how many patients can access the drugs.
Immunogenicity and Unexpected Setbacks
Because bispecific antibodies are more heavily engineered than conventional antibodies, they carry a higher risk of triggering the patient’s immune system to produce antibodies against the drug itself, a phenomenon called immunogenicity. The added mutations, novel chain interfaces, and non-natural structural features can create new epitopes that the patient’s immune system recognizes as foreign. When this happens, the patient develops anti-drug antibodies that neutralize the therapy, reducing its effectiveness and sometimes causing allergic reactions.
This is not a theoretical concern. At least one bispecific antibody built using the knobs-into-holes format exhibited unexpectedly high immunogenicity in both animal studies and human trials, leading to early termination of its clinical development. Detailed investigation revealed that the problem was not the engineered knob-and-hole mutations themselves, but rather epitopes in one of the antibody’s two binding arms. The episode underscores that immunogenicity assessment for bispecific antibodies requires looking at every component, not just the engineering modifications. Each new bispecific product is essentially a unique protein with its own immunogenic profile, and predicting which ones will trigger immune reactions remains imperfect.
Combination Strategies and What Comes Next
One of the most active areas of research is combining bispecific antibodies with other immunotherapies, particularly checkpoint inhibitors like anti-PD-1 or anti-PD-L1 drugs. The rationale is that bispecific antibodies activate T cells against tumors, but those T cells can still be shut down by the tumor’s immunosuppressive defenses. Adding a checkpoint inhibitor removes one of those brakes, potentially amplifying the effect. Preclinical work combining a PD-L1/4-1BB bispecific antibody with pembrolizumab (an anti-PD-1 drug) showed synergistic increases in T-cell cytokine production beyond what either agent achieved alone. Similarly, a bispecific antibody simultaneously blocking TGF-β and VEGF paired with PD-1 blockade produced the most potent and durable anti-tumor effects in preclinical cancer models, with evidence of increased T-cell infiltration into tumors and reinvigorated anti-tumor immunity.
Looking further ahead, the engineering principles behind bispecific antibodies are already being extended to trispecific and other multispecific formats. A trispecific antibody can engage three targets at once, opening possibilities like simultaneously redirecting T cells, blocking an immune checkpoint, and targeting a tumor antigen, all in a single molecule. The idea is that hitting multiple nodes in the immune response and tumor biology at once could improve cancer cell selectivity and reduce the odds of immune escape. These molecules are mostly in early-stage development, but they represent the logical next step of the platform and are attracting significant investment from pharmaceutical companies.
The Cost Question
Bispecific antibodies are expensive drugs, and the economics of their use are under active scrutiny. Cost-effectiveness analyses are beginning to compare different bispecific products head-to-head and against older treatment options. In one analysis conducted from the Spanish healthcare perspective, elranatamab for heavily pretreated multiple myeloma was found to generate roughly 0.92 additional quality-adjusted life years compared to a basket of older physician’s-choice treatments, at a cost considered within acceptable thresholds. When compared directly to teclistamab, another bispecific in the same space, elranatamab was actually less expensive overall while providing more quality-adjusted life years, a result driven largely by differences in dosing schedules and drug costs.
Relative to CAR-T therapy, bispecific antibodies have a clear structural advantage in cost per treatment initiation, since there is no individualized cell manufacturing step. But bispecific antibodies are often given repeatedly over months or years rather than as a one-time infusion, so cumulative costs can climb. The shift toward outpatient administration is one lever for bringing costs down, by eliminating the expensive inpatient monitoring stays that early protocols required. As more bispecific antibodies enter the market and compete with each other, pricing pressure is likely to intensify, which could improve access for patients who currently have few good options.